Star Scientific claimed that the preliminary testing of the compound has produced positive results when applied to cells, and the compound is being explored further for its application to treat a variety of neurological conditions, including Alzheimer’s.
The preliminary tests performed by the Roskamp Institute showed that when the compound developed by Rock Creek is applied to cells, B-amyloid is reduced. Also, the compound appeared to encourage new neuronal cell growth. Results in cells do not necessarily translate to human testing, and additional work needs to be completed to determine whether the compound will have significant B-amyloid lowering effects in humans.
Paul Perito, chairman and CEO of Rock Creek, said: “Jonnie R Williams’ decade-long search for innovative ways to reduce tobacco-related harm fortuitously led to a discovery of a compound that respected and knowledgeable medical researchers at Roskamp Institute believe could play a major role in addressing a variety of neurological conditions including Alzheimer’s disease, which has been the primary focus of Roskamp Institute since its formation.”